News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

SciBase AB Appoints Anna Danström As New Head Of Production And Supply Chain

12/1/2016 11:00:06 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

STOCKHOLM--(BUSINESS WIRE)--SciBase (STO:SCIB), who in June of this year took over the manufacturing of their single-use electrode from Ginolis, has appointed Anna Danström as Supply Chain & Production Manager. Anna Danström, who previously was responsible for electrode development at SciBase, has recently assumed her new role. As Supply Chain & Production Manager Anna becomes a member of the management team, where she replaces Marko Päivärinne.

The insourcing of manufacturing has resulted in a number of advantages for SciBase, including better conditions to pursue the development of more cost-effective larger-scale manufacturing. With Anna as new Supply Chain & Production Manager the work to streamline and scale the production of electrodes in Uppsala will be intensified.

- The manufacturing of electrodes is our most strategically important process and it is of utmost importance that we can both streamline and increase production capacity going forward, a task which Anna is perfectly suited for. With the addition of Anna and also Niklas Jakobsson, who recently assumed responsibility for Quality Assurance and Regulatory issues, we are creating a very strong management team with the relevant competence and experience, says Simon Grant, CEO of SciBase.

Apart from being responsible for the development of electrodes at SciBase Anna has had long experience within medtech, working for a number of international companies such as St. Jude Medicals where she worked in a number of global technology transfer projects. Anna also has experience in working with FDA-related processes, which will be a benefit given SciBase’s on-going PMA process and the forthcoming launch on the US market. Anna replaces Marko Päivärinne who has decided to pursue new challenges outside the company from early next year.

SciBase’s product Nevisense requires a new electrode for every patient examined. SciBase’s business model is based on selling instruments, but the major potential lies in the continuous use of the instruments, which generates revenues from the sale of the single-use electrodes. During the autumn SciBase passed a milestone of 10,000 electrodes sold during the year and increased sales of the electrodes by 77 percent for the first nine months of the year.

For further information please visit

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on December 1, 2016.

About Skin Cancer

Skin cancer is one of the most common cancers in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to the age of 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75%) of deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly.

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on

This information was brought to you by Cision


Simon Grant, CEO
Tel: +46 72 887 43 99

Read at

comments powered by Disqus